One Sentence Summary: miR-17~92 expression in Myc + tumors sensitizes cancer cells to biguanide treatment by disrupting bioenergetic stability in lymphoma cells.
Introduction
A major driver of metabolic reprogramming in cancer is the c-Myc proto-oncogene (Myc), a transcription factor that broadly regulates the expression of genes involved in anabolic metabolism and cellular bioenergetics (1) . Oncogene activation or tumor suppressor inactivation promotes changes in cellular metabolism that facilitate transformation and tumor cell proliferation (2) . However, the increased metabolic activity stimulated by transformation imposes additional stresses on tumor cells such as nutrient depletion and redox imbalance, which must be countered in order for tumors to survive and grow. The Liver Kinase B1 (LKB1)/AMPactivated protein kinase (AMPK) pathway contributes to tumor cell survival by promoting cellular sensing of and adaptation to such bioenergetic stress (3) . Inactivation of LKB1 in cancer, conversely, promotes anabolic metabolic reprogramming at the expense of metabolic flexibility (4) (5) (6) (7) . In cells lacking LKB1, including non-small cell lung cancer (NSCLC), AMPK activation is reduced and cells are more sensitive to metabolic stresses induced by nutrient limitation or inhibitors of oxidative phosphorylation (OXPHOS) (8, 9) . This raises the possibility of using OXPHOS inhibitors to target cancers with reduced bioenergetic capacity and/or defects in energy-sensing control systems. Indeed, potent OXPHOS inhibitors (for example IACS-010759) (10) , putative inhibitors of mitochondrial protein synthesis (11, 12) , and enhancers of degradation of respiratory chain proteins (13, 14) are all under study as antineoplastic strategies.
Biguanides represent another class of drugs proposed to target cellular bioenergetics in tumor cells. The most well-known biguanide is metformin-a drug commonly used to treat type II diabetes. Metformin reduces the activity of mitochondrial complex I, thereby limiting mitochondrial ATP production and imposing bioenergetic stress on cells (15, 16) . This leads to reduced hepatic gluconeogenesis and reduced hyperglycemia in type II diabetes. However, if adequate drug levels can be achieved in other cell types, lineage-specific consequences of energetic stress are observed, including cytostatic or cytotoxic effects on cancer cells (17) . Older retrospective studies (18) reported that diabetics treated with metformin had reduced cancer risk and better cancer prognosis relative to diabetic patients not taking metformin (18) , generating interest in repurposing biguanides as anti-cancer agents (17) . However, further pharmacoepidemiologic studies (19, 20) failed to confirm these findings, and early randomized clinical trials of metformin in advanced cancer have shown no survival benefit in pancreatic cancer (21) , and only minor benefit in lung cancer (22) . Pharmacokinetic factors, such as the requirement for active transport of metformin by the organic cation 1 (OCT1) transporters, may account in part to the discrepancies between preclinical models and clinical trials with respect to anti-cancer effects of metformin. Nevertheless, many in vivo cancer models demonstrate significant in vivo antineoplastic activity of biguanides (6, (23) (24) (25) (26) (27) , raising the possibility that biguanides with better bioavailability and toxicity profiles may have clinical utility. Important in the clinical development of OXPHOS inhibitors as antineoplastic drugs is selection of subsets of cancers that are particularly sensitive to metabolic stress. Preclinical work by Shackelford et al. demonstrated that biguanides, specifically phenformin, could be effective as single agents for LKB1-deficient , in keeping with LKB1's role in adaptation to energetic stress. While mutation of LKB1 is found in ~20-30% of NSCLC, we hypothesized that biguanide-sensitive cancers can be extended to those with increased expression of MYC, which we have previously reported promotes translational suppression of LKB1 via the miRNA miR-17~92 (28) . In this study, using loss-and gain-of-function models of miR-17~92, we demonstrate that elevated miR-17~92 expression, specifically the seed family miR17/20, confers increased sensitivity of mouse and human lymphoma cells to apoptosis induced by two biguanides-phenformin and the novel biguanide IM156. As single agents, both phenformin and IM156, but not metformin, extended the survival of mice bearing miR-17~92-expressing lymphomas. Collectively, these results suggest that miR-17~92 could potentially function as a biomarker for biguanide sensitivity in lymphomas.
Results

IM156 is a novel biguanide that inhibits mitochondrial respiration.
The limited bioavailability of metformin and its dependence on OCT1 for cellular uptake potentially limits its applicability in the treatment of cancer (29) . We investigated the biological properties of phenformin and the novel biguanide IM156, which are more hydrophobic and therefore potentially more bioavailable to cells than metformin ( Figure 1A) . To test the impact of these biguanides on tumor cell respiration, we acutely treated Myc-dependent mouse lymphoma cells (Eµ-Myc cells) with either metformin, phenformin, or IM156 and assessed changes in oxygen consumption rate (OCR) using the Seahorse XF96 extracellular flux analyzer. Across a range of concentrations, phenformin and IM156 decreased OCR (Figures 1B) , with IM156 exhibiting greater potency than phenformin and metformin at equal concentrations.
IM156 was more effective than phenformin at reducing cellular ATP production at equal concentrations, correlating with the effect of IM156 on oxidative phosphorylation ( Figure 1C) .
These data are consistent with IM156 functioning as a more potent inhibitor of mitochondrial respiration than phenformin.
We next determined if phenformin and IM156 similarly activate the energy sensor AMPK, as depletion of cellular ATP by biguanide treatment is a known trigger for AMPK activation (30) . Given the difference in potency of phenformin and IM156, we used doses (100 µM and 10 µM, respectively) that produced an equivalent ~50% decrease in OCR from baseline after two hours treatment (Figure S1A-B) . Two-hour treatment with these concentrations of phenformin or IM156 yielded similar levels of AMPK phosphorylation (Figure 1D) . Lastly, we treated Eµ-Myc + lymphoma cells with a range of concentrations of both phenformin and IM156.
Based on cell viability measurements, IM156 exhibited higher potency and induced lymphoma cell death at lower concentrations than phenformin (EC 50 of 12 µM for IM156 compared to 62 µM for phenformin, Figure 1E ).
miR-17~92 sensitizes lymphoma cells to apoptosis by biguanides
We previously demonstrated that the oncogenic miRNA cluster miR-17~92 is required for Myc-dependent metabolic reprogramming in lymphoma and does so in part through translational suppression of LKB1 (28) . We next examined whether expression of miR-17~92 alters the sensitivity of lymphoma cells to biguanide treatment. We used Eµ-Myc B cell lymphoma cells harboring floxed miR-17~92 alleles, which allowed us to study the effect of conditional deletion of miR-17~92 in the presence of constitutive Myc expression (31) . Eµ-Myc lymphoma cells deleted for miR-17~92 (Δ/Δ) were more resistant to phenformin treatment than their isogenic counterparts expressing miR-17~92 (fl/fl) (Figure 2A) . Phenformin treatment actively induced apoptosis in miR-17~92-expressing Eµ-Myc lymphoma cells as shown by the presence of active (cleaved) caspase-3 ( Figure 2B) . Levels of caspase-3 cleavage were markedly reduced in Eµ-Myc lymphoma cells lacking miR-17~92 (Figure 2B) .
Since miR-17~92 is recurrently amplified in lymphoma (32, 33) , we next tested whether increased copy number of miR-17~92 was sufficient to increase the sensitivity of lymphoma cells to biguanides. To test this, we generated Eµ-Myc lymphoma cells and Raji lymphoma cells-a human Burkitt's lymphoma cell line known to display low Myc levels (28)-with ectopic expression of the entire miR-17~92 polycistron (hereafter denoted as +17~92). Eµ-Myc lymphoma cells overexpressing miR-17~92 were significantly more sensitive than control cells when treated with either phenformin or IM156 (Figure 2C and S1A) . miR-17~92 overexpression led to a 10-fold shift in the EC 50 of Eµ-Myc cells to IM156 treatment (2 μM versus 24 μM).
Similar results were observed in Raji cells engineered to express higher levels miR-17~92 (Figure 2D-E and S1B). Although Raji cells were less sensitive to biguanide treatment, with EC 50 ranging from 90-3500 µM as compared to Eµ-Myc + EC 50 ranging from 2-62 µM ( Figure   S1A -B), overexpression of miR-17~92 still conferred a ~3-fold increase in sensitivity to biguanides compared to control cells. These data indicate that elevated miR-17~92 enhances sensitivity of lymphoma cells to biguanide treatments, and that Myc and miR-17~92 synergize to increase sensitivity to biguanide treatment.
We next asked whether the enhanced sensitivity to biguanides observed in vitro extended to in vivo models. Nude mice harboring either control or miR-17~92-overexpressing Eµ-Myc cells were administered phenformin or IM156 in their drinking water ad libitum and survival was tracked compared to tumor-bearing mice administered regular drinking water. While biguanide treatment of mice bearing control lymphoma cells produced no discernable survival benefit ( Figure 3A) , both phenformin and IM156 significantly prolonged the lifespan of mice bearing aggressive miR-17~92-overexpressing tumors (Figure 3B) . Our observations indicate that phenformin and IM156 can act as single agents to extend survival of mice bearing tumors with elevated miR-17~92 expression. Together these data indicate that elevated miR-17~92 expression is a predictor of sensitivity to biguanides.
miR-17~92 confers sensitivity to biguanides through suppression of LKB1
We next explored the mechanism by which elevated miR-17~92 expression confers biguanide sensitivity in lymphoma cells. Non-small cell lung cancer (NSCLC) cells that have lost LKB1 display increased sensitivity to phenformin (8) . We previously identified LKB1 as a Given that an increased copy number of miR-17~92 leads to LKB1 repression in lymphoma cells (Figure 4B) , we tested whether AMPK activation was differentially engaged downstream of either phenformin or IM156 treatment. Lymphoma cells overexpressing miR-17~92 displayed reduced AMPK phosphorylation following phenformin or IM156 treatment compared to control cells (Figure 4F ), suggesting uncoupling of the LKB1-AMPK axis to metabolic stress (Figure 4G) .
Biguanide treatment affects central carbon metabolism in miR-17~92-expressing Myc + lymphoma cells
We next characterized the effect of IM156 treatment on lymphoma cell bioenergetics using a Seahorse XF96 extracellular flux analyzer. Lymphoma cells overexpressing miR-17~92 exhibit higher basal metabolic rate-both in terms of glycolytic rate (ECAR) and respiration (OCR)-than control cells (Figure 5A) . This corresponded to higher overall rates of ATP production by miR-17~92-expressing lymphoma cells compared to controls, which was due largely to increased glycolytic ATP production ( Figure 5B) . miR-17~92-expressing lymphoma cells also displayed a larger bioenergetic scope than control cells (Figure 5C) . The bioenergetic profile of both cell types was significantly altered by IM156 treatment, characterized by a drop in mitochondrial ATP production (J ATP ox) and slight increase in glycolytic ATP production (J ATP gly) (Figure 5C ). IM156 reduced OXPHOS-derived ATP production in both cell types by greater than 50% (Figure 5C) .
We next examined the impact of biguanide treatment on metabolite dynamics in lymphoma cells. Consistent with their increased bioenergetic profile (Figure 5A-C) , miR-17~92-expressing lymphoma cells displayed increased abundance of metabolites involved in glycolysis (e.g., pyruvate, lactate), TCA cycle (e.g., citrate, succinate, fumarate, malate), and amino acid metabolism (Figure 5D ). Biguanide treatment had minimal effect on amino acid levels in either cell type (Figure 5D ). However, levels of TCA cycle intermediates were markedly reduced in miR-17~92-expressing cells upon treatment with phenformin or IM156 (Figure 5D ), suggesting that biguanide treatment limits metabolite flux through the TCA cycle.
This was not due to an inhibition of glucose or glutamine uptake, as 13 C-tracing experiments revealed no change in glucose trafficking to lactate (Figure 5E ) or glutamine uptake (Figure 5F) in the presence of phenformin or IM156. Biguanide treatment blunted 13 C-glucose and 13 Cglutamine entry into the TCA cycle, as evidenced by reduced conversion of glucose and glutamine to citrate (Figure 5G) . 13 C-glutamine-derived production of aspartate, a key intermediate for protein and nucleotide biosynthesis and tumor cell growth (34, 35) , was reduced by 60-65% following 2 h administration of phenformin or IM156. These data suggest that although miR-17~92 enhances central carbon metabolism and bioenergetic potential in lymphoma cells, these pathways are uniquely sensitive to biguanide treatment.
miR-17/20 expression correlates with biguanide sensitivity in human lymphoma cells
Having defined the downstream effects of biguanides on the metabolism and viability of miR-17~92-expressing Myc + lymphoma cells, we expanded our analysis to test biguanide sensitivity in a panel of human lymphoma cell lines. Ten verified Myc + lymphoma cell lines were used for this analysis: SU-DHL-4, OCI-Ly7, Jeko-1, Rec-1, Karpas 1718, OCI-Ly-1, OCI-Ly-2, OCI-Ly-3, OCI-Ly-8, and OCI-Ly-18. For each cell line we measured levels of both the primary (pri-miR) and mature (miR) forms of miR-17 and miR-20 and determined the EC 50 for cell viability to phenformin or IM156. From these data, we observed a negative correlation between the relative level of miR-17/20 expressed in cells and the dose of biguanide required to achieve EC 50 (Figure 6A-B and S2) , with cells displaying the highest miR-17/20 expression showing the greatest sensitivity to biguanide treatment. Levels of pri-miR-17 were a better predictor of biguanide sensitivity than mature miR-17 (Figure 6A-B) . IM156 was more potent than phenformin in inducing cell death in human lymphoma cells, similar to that observed in Eµ-Myc + lymphoma cells. Together these data demonstrate miR-17 expression levels to be a biomarker for biguanide sensitivity.
Discussion
Myc is abnormally expressed in many human cancers; however, development of small molecule Myc inhibitors has been a persistent challenge (36) , prompting consideration of alternative approaches to Myc targeting. Here we report that a downstream target of Myc-driven metabolism-miR-17~92-while increasing bioenergetic capacity of tumor cells, also increases sensitivity to apoptosis induced by biguanides. Using both classic (phenformin) and novel (IM156) biguanides, we demonstrated that human and mouse lymphoma cells with elevated miR-17~92 expression are highly sensitized to biguanide treatment. As single agents, both phenformin and IM156 were effective at extending survival of mice bearing miR-17~92expressing lymphomas. In addition, we observed a statistical correlation between miR-17 levels in human lymphoma cells and sensitivity to biguanide treatment. Together our data provide rationale for the clinical investigation of miR-17~92 expression level as a potential biomarker for biguanide sensitivity in cancer.
Enhanced Myc activity leads to overexpression of miR-17~92, which in turn lowers LKB1 expression. This leads to enhanced tumor growth associated with increased glycolysis and oxidative phosphorylation, but it also reduces the capacity of lymphoma cells to activate the LKB1-AMPK system to overcome the energetic stress imposed by biguanides. Another important function of LKB1-AMPK signaling is the surveillance of mitochondrial integrity (37) .
The potential impact of miR-17~92 on mitochondrial homeostasis and changes in response to biguanide treatment remains to be determined.
Our results address gaps in knowledge related to the mechanism by which LKB1 loss induces biguanide sensitivity. Previous work indicates that phenformin treatment increases ROS levels in cells with reduced LKB1 expression (8) , leading to oxidative damage and preferential cell death of LKB1-null tumor cells. We show here that glucose-and glutamine-dependent fueling of the TCA cycle was inhibited in miR-17~92-expressing lymphoma cells responding to biguanide treatment. This fueling is a key node for the production of reducing equivalents for ATP production and biosynthetic intermediates for growth (e.g., citrate and aspartate). Our data are consistent with observations that reducing mitochondrial aspartate production in tumor cells can impair cell viability, due in part to diminished purine and pyrimidine biosynthesis (38, 39) .
Reduced biosynthetic metabolism, combined with reduced mitochondrial NADH production and an inability to activate AMPK signaling, appear to sensitize miR-17~92-expressing lymphoma to metabolic stress. Consistent with this, biguanide treatment-particularly IM156-slowed lymphoma cell growth in vitro and extended the lifespan of tumor-bearing mice.
There has been increased interest in the clinical use of biguanides for cancer therapy.
Encouraging preclinical data (17) led to more than 100 clinical trials of metformin for indications in oncology (21) , but early results have been disappointing. Lack of clinical benefit of metformin in trials reported to date does not necessarily imply that biguanides as a class have no activity.
Pharmacokinetic factors may account at least in part for the discrepancies between preclinical models and clinical trials with respect to antineoplastic activity of metformin. The hydrophilic nature of metformin dictates that cellular uptake is dependent on organic cation 1 (OCT1) transporters before gaining access to mitochondria (29) . This inherently limits the action of metformin to those cells expressing OCT1, which can vary between tumors (40) . The biguanide phenformin displays greater bioavailability and anti-neoplastic activity than metformin (29, 40, 41) , but its clinical use has been limited due to the risk of lactic acidosis, especially in patients with compromised renal or liver function (42) . These results justify investigation of novel biguanides with better pharmacokinetic/pharmacodynamic (PK/PD) properties than metformin in neoplastic tissue as a strategy for OXPHOS inhibition for cancer treatment. We identified IM156 from a library of >1,000 biguanides as a potential anti-cancer drug candidate (43) . Our data indicate that IM156 is a more potent OXPHOS inhibitor than metformin or phenformin. IM156 may have advantages over metformin as it is a more potent, hydrophilic biguanide that we hypothesize is more bioavailable in neoplastic tissues. IM156 is presently being evaluated in a phase I clinical trial (NCT 032 72256).
Our research adds to prior evidence (8, 44) that clinical trials of biguanides or other OXPHOS inhibitors are likely to show clinical activity if evaluated in patients with cancers that are particularly sensitive to energetic stress, such as those with elevated expression of Myc or miR-17~92 and/or decreased function of LKB1. Although LKB1 inactivation is relatively common in NSCLC (7), it is not common amongst other malignancies. In contrast, Myc is among the most commonly dysregulated oncogenes in both hematologic malignancies and solid tumors.
Because of the paucity of viable treatments targeting Myc-driven cancers, linking the downstream Myc target miR-17~92 to inhibition of LKB1 may identify a cohort of patients without LKB1 mutations who are particularly sensitive to biguanide treatment, opening new avenues for the treatment of these cancers.
Materials and Methods
Synthesis of IM156
IM156 was synthesized as previously reported (45) . In brief, pyrrolidine was dissolved in butanol before concentrated hydrochloric acid was added and stirred for 30 min at 0°C. Sodium dicyanamide was then added and stirred for 24 h under reflux. After completion of the reaction was confirmed, the adduct-N1-pyrollidine cyanoguanidine-was purified. Next, phenylamine was dissolved in butanol before concentrated hydrochloric acid was added and stirred for 30 min at room temperature. The N1-pyrollidine cyanoguanidine prepared above was then added and stirred for 6 h under reflux. This mixture was concentrated under reduced pressure then dissolved in a 6 N hydrochloric acid/methanol solution before adding ethyl acetate. The precipitate-IM156A HCl-was filtered and dried under reduced pressure. IM156.HCl can be converted to free form by adding sodium hydroxide. The free form can be converted to the acetate salt form-IM156A-by adding acetic acid.
Cell lines, DNA constructs, and cell culture
The generation of Eµ-Myc Cre-ERT2 + ; miR-17~92 fl/fl lymphoma cells has been described previously (31) . Deletion of miR-17~92 was achieved by culturing Eµ-Myc Cre-ERT2 + ;miR- Retroviral-mediated gene transfer into lymphoma cells was conducted as previously described (46) . Briefly, lymphoma cells were transduced via spin infection, followed by culture in 4 µg/mL puromycin for four days, and subsequent subcloning by limiting dilution. miR-17~92 constructs have been previously described (31) . Knockdown of Stk11 via shRNA (sequence: 5'-AGGTCAAGATCCTCAAGAAGAA -3') has been described (28) .
Cell proliferation and viability assays
Cells were seeded at a density of 1 x 10 5 cells/mL in 3.5 cm dishes, and cell counts determined via trypan blue exclusion using a TC20 Automated Cell Counter (Biorad). For viability measurements, cells were stained with Fixable Viability Dye eFluor 780 (eBioscience), and analyzed using a Gallios flow cytometer (Beckman Coulter, Fullerton, CA) and FlowJo software (Tree Star, Ashland, OR).
Seahorse XF96 Respirometry and metabolic assays
Cellular oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) using established protocols (4, 47) . In brief, 7.5 x 10 4 lymphoma cells were plated per well of an XF96 Seahorse plate in 140 μ L of unbuffered DMEM containing 25 mM glucose and 2 mM glutamine, followed by centrifugation at 500xg for five minutes. Seahorse plates were pre-coated with poly-D-lysine (Sigma-Aldrich) to enhance cell adherence. XF assays consisted of sequential mix (3 min), pause (3 min), and measurement (5 min) cycles, allowing for determination of OCR and ECAR every 8 min. Following four baseline measurements, 20 µL of untreated media, phenformin, or IM156 were injected into respective wells, and OCR and ECAR tracked over time.
GC-MS analysis of 13 C-labelled metabolites
Cellular metabolites were extracted and analyzed by GC-MS using previously described protocols (4, 26, 48) . Eµ-Myc cells (3-5 × 10 6 per 3.5 cm dish) were incubated for 2 hours in untreated, 100 µM phenformin, or 10 µL IM156 medium containing 10% dialyzed FBS and was used for all GC-MS experiments, and data collected by electron impact set at 70 eV. A total of 1 μL of derivatized sample was injected per run in splitless mode with inlet temperature set to 280˚C, using helium as a carrier gas with a flow rate of 1.5512 mL/min (rate at which D27myristic acid elutes at 17.94 min). The quadrupole was set at 150˚C and the GC/MS interface at 285˚C. The oven program for all metabolite analyses started at 60˚C held for 1 min, then increasing at a rate of 10˚C/min until 320˚C. Bake-out was at 320˚C for 10 min. Sample data were acquired in scan mode (1-600 m/z). (48) Mass isotopomer distribution for TCA cycle intermediates was determined using a custom algorithm developed at McGill University (48) .
After correction for natural 13 C abundances, a comparison was made between non-labeled ( 12 C) and 13 C-labeled abundances for each metabolite. Metabolite abundance was expressed relative to the internal standard (D-myristic acid) and normalized to cell number.
Immunoblotting and Quantitative Real-Time PCR
Lymphoma cell lines were subjected to SDS-PAGE and immunoblotting using CHAPS and AMPK lysis buffers as previously described (46) . Primary antibodies against β -actin, 4EBP (total, phospho-T36/47, and phospho-S65), rS6 (total and p S235/236), Raptor (total and pS792), and AMPKα (total and phospho-T172) were obtained from Cell Signaling Technology (Danvers, MA). Primary antibody against LKB1 (Ley 37D/G6) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). For qPCR quantification of mature miRNAs, Qiazol was used to isolate RNA, miRNEasy Mini kit was used to purify miRNAs and total mRNA, and cDNA wassynthesized using the miScript II RT kit (Qiagen). Quantitative PCR was performed using the SensiFAST SYBR Hi-ROX kit (Bioline) and an AriaMX Real Time PCR system (Agilent Technologies). miScript primer assays (Qiagen) were used to detect mature miRNAs of the miR-17~92 cluster, with miRNA expression normalized relative to U6 RNA levels.
Tumor xenograft assays
Lymphoma cells were resuspended in HBSS at a concentration of 5 x 10 6 cells/mL, and 10 6 cells/200 μ L were injected intravenously into CD-1 nude mice (Charles River). Water bottles carrying 1.2% sucralose, 0.9 mg/mL phenformin +1.2% sucralose, or 0.8 mg/mL IM156 + 1.2% sucralose were provided for ad lib consumption. Mice were tracked until clinical displays of disease, such as weight loss and poverty of movement, at which point mice were euthanized.
Statistical Analysis
Statistics were determined using paired Student's t-test, ANOVA, or Log-rank (Mantel-Cox) using Prism software (GraphPad) unless otherwise stated. Data are calculated as the mean ± SEM for biological triplicates, and the mean ± SD for technical replicates unless otherwise stated. Statistical significance is represented in figures by: *, p<0.05; **, p<0.01; ***, p<0.001 Table S1 , related to Fig. 6 . EC 50 and miR17/20 expression in human lymphoma cell lines Fig. 1. IM156 is a novel biguanide that inhibits mitochondrial respiration.
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(B) Dose-dependent reduction of OCR of Eµ-Myc + lymphoma cells by metformin, phenformin, and IM156. Data were derived from the maximal point of OCR reduction after 30 minutes of treatment with the indicated biguanide and expressed relative to untreated cells at the same timepoint. Data represent mean ± SEM for biological replicates (n = 4-6 per drug per concentration).
